Nguyen Louis L
Division of Vascular & Endovascular Surgery, and the Center for Surgery and Public Health, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
J Vasc Surg. 2007 Jun;45 Suppl A(Suppl A):A149-57. doi: 10.1016/j.jvs.2007.02.029.
Peripheral arterial disease (PAD) is a growing health problem for many Americans and often occurs along with other cardiovascular risk factors, including diabetes mellitus (DM), low-grade inflammation, hypertension, and lipid disorders. Intermittent claudication (IC), an early manifestation of PAD, commonly leads to reduced quality of life for patients who are limited in their ambulation. While recent wide adoption of percutaneous peripheral interventional (PPI) techniques has increased the number patients being aggressively treated for IC, the overall effectiveness of PPI for the treatment of IC is not well known, especially for DM patients who have both hemodynamic and functional obstacles to treatment success. This review is designed to illustrate how treatment outcomes for IC can be measured by different modalities and how diabetes and inflammation can influence those outcomes. In the setting of greater concern for health care resources and clinical accountability, better understanding of treatment outcomes and efficacy will help us manage these complex challenges.
外周动脉疾病（PAD）对许多美国人来说是一个日益严重的健康问题，并且常常与其他心血管危险因素同时出现，包括糖尿病（DM）、低度炎症、高血压和脂质紊乱。间歇性跛行（IC）是PAD的早期表现，通常会导致行动受限的患者生活质量下降。虽然最近经皮外周介入（PPI）技术的广泛应用增加了积极治疗IC的患者数量，但PPI治疗IC的总体有效性尚不清楚，尤其是对于那些在治疗成功方面存在血流动力学和功能障碍的糖尿病患者。本综述旨在说明如何通过不同方式测量IC的治疗结果，以及糖尿病和炎症如何影响这些结果。在对医疗资源和临床责任更为关注的背景下，更好地理解治疗结果和疗效将有助于我们应对这些复杂挑战。
